[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUE053158T2 - Clopidogrelt és szulfoalkiléter ciklodextrint tartalmazó készítmények és alkalmazási eljárások - Google Patents

Clopidogrelt és szulfoalkiléter ciklodextrint tartalmazó készítmények és alkalmazási eljárások

Info

Publication number
HUE053158T2
HUE053158T2 HUE08769199A HUE08769199A HUE053158T2 HU E053158 T2 HUE053158 T2 HU E053158T2 HU E08769199 A HUE08769199 A HU E08769199A HU E08769199 A HUE08769199 A HU E08769199A HU E053158 T2 HUE053158 T2 HU E053158T2
Authority
HU
Hungary
Prior art keywords
methods
formulations containing
sulfoalkyl ether
ether cyclodextrin
containing clopidogrel
Prior art date
Application number
HUE08769199A
Other languages
English (en)
Inventor
Gerold Mosher
Rebecca Wedel
Karen Johnson
Stephen Machatha
Jane Cowee
Daniel Cushing
Original Assignee
Cydex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cydex Pharmaceuticals Inc filed Critical Cydex Pharmaceuticals Inc
Publication of HUE053158T2 publication Critical patent/HUE053158T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
HUE08769199A 2007-04-27 2008-04-26 Clopidogrelt és szulfoalkiléter ciklodextrint tartalmazó készítmények és alkalmazási eljárások HUE053158T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91455507P 2007-04-27 2007-04-27

Publications (1)

Publication Number Publication Date
HUE053158T2 true HUE053158T2 (hu) 2021-06-28

Family

ID=39926106

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE08769199A HUE053158T2 (hu) 2007-04-27 2008-04-26 Clopidogrelt és szulfoalkiléter ciklodextrint tartalmazó készítmények és alkalmazási eljárások

Country Status (18)

Country Link
US (6) US8343995B2 (hu)
EP (2) EP2152078B8 (hu)
JP (4) JP5681485B2 (hu)
KR (3) KR101753131B1 (hu)
CN (2) CN101686681B (hu)
AU (1) AU2008245550B2 (hu)
BR (1) BRPI0809838B1 (hu)
CA (2) CA2685331C (hu)
DK (1) DK2152078T3 (hu)
ES (1) ES2855700T3 (hu)
HK (1) HK1212909A1 (hu)
HU (1) HUE053158T2 (hu)
IL (1) IL201776A (hu)
MX (1) MX2009011619A (hu)
NZ (1) NZ581362A (hu)
RU (1) RU2470636C2 (hu)
SI (1) SI2152078T1 (hu)
WO (2) WO2008134600A1 (hu)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2647348A1 (en) 2006-03-28 2007-10-04 Javelin Pharmaceuticals, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
DK2152078T3 (da) 2007-04-27 2021-02-08 Cydex Pharmaceuticals Inc Formuleringer indeholdende clopidogrel og sulfoalkylethercyclodextrin og anvendelsesfremgangsmåder
EP2265731A4 (en) * 2008-01-25 2012-01-18 Theranostics Lab METHODS AND COMPOSITION FOR EVALUATING MEDICATION RESPONSE
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
WO2009133455A2 (en) * 2008-05-01 2009-11-05 Cadila Healthcare Limited Pharmaceutical composition of clodipogrel
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
FR2932387B1 (fr) * 2008-06-16 2010-09-17 Cll Pharma Composition orale contenant un agent anti-plaquettaire de la famille des thienopyridines sous forme de base.
WO2010053487A1 (en) 2008-11-07 2010-05-14 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
PT3100728T (pt) 2009-05-13 2020-02-21 Cydex Pharmaceuticals Inc Composições farmacêuticas que compreendem prasugrel e derivados da ciclodextrina e métodos de produção e utilização dos mesmos
US7803762B1 (en) 2009-08-20 2010-09-28 The Medicines Company Ready-to-use bivalirudin compositions
EA028885B1 (ru) 2009-11-11 2018-01-31 Чиези Фармачеутичи С.П.А. Способы лечения или предотвращения тромбоза стента и инфаркта миокарда (варианты)
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
US8563574B2 (en) * 2009-12-07 2013-10-22 Academic Pharmaceuticals, Inc. Parenteral formulation of clopidogrel
WO2011101865A2 (en) * 2010-02-19 2011-08-25 Cadila Healthcare Limited Stable pharmaceutical compositions of clopidogrel for parenteral delivery
CN102232949A (zh) * 2010-04-27 2011-11-09 孙远 提高药物溶出度的组合物及其制备方法
WO2012122493A1 (en) * 2011-03-10 2012-09-13 Jina Pharmaceuticals, Inc. Lipid based clopidogrel compositions, methods, and uses
BR112014013924A2 (pt) * 2011-12-09 2017-06-13 Wockhardt Ltd métodos para tratar distúrbios cardiovasculares
AU2013215237B2 (en) * 2012-01-30 2017-11-23 Baxalta GmbH Non-anticoagulant sulfated or sulfonated polysaccharides
US9009933B2 (en) * 2012-02-02 2015-04-21 Astrid Lombardi Method to improve the appearance of a corpse and new thanatocosmetic compositions
PT3702374T (pt) 2012-02-15 2022-06-23 Cydex Pharmaceuticals Inc Processo de fabrico para derivados de ciclodextrina
RU2747757C2 (ru) * 2012-02-28 2021-05-13 Сидекс Фармасьютикалс, Инк. Композиции алкилированного циклодекстрина и способы их получения и применения
EA032006B1 (ru) 2012-10-22 2019-03-29 Сидекс Фармасьютикалс, Инк. Композиции алкилированного циклодекстрина и способы их получения и применения
JP6552967B2 (ja) * 2013-02-06 2019-07-31 ホアン，ジンジュン 経口および非経口送達用のクロピドグレル遊離塩基の安定な医薬組成物
EP2968390A4 (en) * 2013-03-15 2016-10-26 Epizyme Inc INJECTABLE FORMULATIONS FOR THE TREATMENT OF CANCER
EP2971287B1 (en) 2013-03-15 2019-08-14 GPB Scientific, LLC On-chip microfluidic processing of particles
WO2014145075A2 (en) 2013-03-15 2014-09-18 The Trustees Of Princeton University Methods and devices for high throughpout purification
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
EP3521442B1 (en) 2013-07-15 2023-05-03 President and Fellows of Harvard College Assays for antimicrobial activity and applications thereof
GB201312737D0 (en) * 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
JP6914188B2 (ja) 2014-08-22 2021-08-04 サイデックス・ファーマシューティカルズ・インコーポレイテッド 分画アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
US20170290765A1 (en) * 2014-09-17 2017-10-12 Epizyme, Inc. Injectable formulations for treating cancer
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2017035262A1 (en) * 2015-08-24 2017-03-02 Gpb Scientific, Llc Methods and devices for multi-step cell purification and concentration
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
PL3256138T3 (pl) * 2015-11-25 2022-08-01 Axsome Therapeutics, Inc. Kompozycje farmaceutyczne zawierające meloksykam
WO2018090096A1 (en) * 2016-11-18 2018-05-24 The University Of Western Australia Taste masking product
ES2901427T3 (es) * 2016-12-14 2022-03-22 Sk Biopharmaceuticals Co Ltd Preparación líquida parenteral que comprende un compuesto de carbamato
CA3063095A1 (en) * 2017-05-10 2018-11-15 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising an nsaid
MX2019015448A (es) 2017-06-23 2020-02-19 Chiesi Farm Spa Metodo para la prevencion de trombosis de desviacion de la arteria sistemica a pulmonar.
CN110711180B (zh) * 2018-07-13 2022-03-29 武汉武药科技有限公司 一种替格瑞洛组合物及其制备方法
WO2020101627A1 (en) * 2018-11-14 2020-05-22 Canakkale Onsekiz Mart Universitesi Rektorlugu A solution developed to be applied to the saphenous vein graft
CA3123718A1 (en) 2019-01-04 2020-07-09 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
WO2020141226A1 (en) * 2019-01-04 2020-07-09 Sq Innovation Ag Pharmaceutical compositions of torsemide and uses thereof
CN109674744B (zh) * 2019-01-21 2021-09-17 成都欣捷高新技术开发股份有限公司 稳定的盐酸替罗非班液体组合物及其制备方法
US11992514B2 (en) 2019-05-20 2024-05-28 MAIA Pharmaceuticals, Inc. Ready-to-use bivalirudin compositions
US11739952B2 (en) 2020-07-13 2023-08-29 Rheem Manufacturing Company Integrated space conditioning and water heating/cooling systems and methods thereto
WO2023012479A1 (en) 2021-08-03 2023-02-09 Liqmeds Worldwide Limited An oral pharmaceutical solution of clopidogrel
TW202339745A (zh) * 2022-01-28 2023-10-16 大陸商上海柯君醫藥科技有限公司 抗血小板藥物的藥物組合物及其用途
CN115902237B (zh) * 2022-11-09 2024-09-27 哈尔滨医科大学 用于判断急性心肌梗死后心源性猝死的生物标志物及其应用

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426011A (en) * 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
FR2530247B1 (fr) 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
US4927013A (en) * 1989-04-12 1990-05-22 Eastman Kodak Company Package for storing and remixing two materials
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR927003645A (ko) 1990-05-21 1992-12-18 후지다 히로미찌 씨클로덱스트린 유도체
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5576328A (en) * 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
US5632275A (en) * 1994-09-16 1997-05-27 Scribner-Browne Medical Design Incorporated Catheter lab table pad and method for using the same
FR2744918B1 (fr) * 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
FR2751540B1 (fr) * 1996-07-26 1998-10-16 Sanofi Sa Composition pharmaceutique antithrombotique
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
ID23908A (id) 1997-06-05 2000-05-25 Lilly Co Eli Metode pengobatan dari penyakit trombosis
ES2210769T3 (es) 1997-06-13 2004-07-01 Cydex Inc. Compuesto con vida de almacenamiento prolongada que comprende ciclodextrina y medicamentos y promedicamentos que se descomponen en componentes insolubles en agua.
PT889056E (pt) * 1997-07-01 2006-07-31 Pfizer Prod Inc Processo para produzir um,a ciclodextrina.
US20010044584A1 (en) * 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
FR2769313B1 (fr) 1997-10-06 2000-04-21 Sanofi Sa Derives d'esters hydroxyacetiques, leur procede de preparation et leur utilisation comme intermediaires de synthese
JP2003522207A (ja) 1998-02-23 2003-07-22 サイクロプス・イーエイチエフ 高エネルギーシクロデキストリン複合体
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
PT1087775E (pt) 1998-06-17 2005-11-30 Bristol Myers Squibb Co Prevencao de enfarte cerebral por administracao de uma combinacao de farmacos antiplaquetarios bloqueadores de receptores de adp e anti-hipertensivos
DE19836021A1 (de) 1998-08-10 2000-03-09 Weitmann & Konrad Fa Pudervorrichtung
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
ES2276801T3 (es) 2000-07-06 2007-07-01 Sankyo Company, Limited Sales de adicion acidas de derivados de la hidropiridina.
JP4874482B2 (ja) 2000-12-25 2012-02-15 第一三共株式会社 アスピリンを含有する医薬組成物
PL206138B1 (pl) 2000-12-25 2010-07-30 Daiichi Sankyo Company Limiteddaiichi Sankyo Company Limited Kompozycja farmaceutyczna zawierająca aspirynę oraz zestaw i zastosowanie składników kompozycji
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US20080220441A1 (en) * 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
RU2004102500A (ru) * 2001-06-29 2005-04-10 Максиген Апс (Dk) Композиции интерферонов
CA2363053C (en) 2001-11-09 2011-01-25 Bernard Charles Sherman Clopidogrel bisulfate tablet formulation
US6767913B2 (en) 2001-12-18 2004-07-27 Teva Pharmaceutical Industries Ltd. Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms
US7074928B2 (en) * 2002-01-11 2006-07-11 Teva Pharmaceutical Industries, Ltd. Polymorphs of clopidogrel hydrogensulfate
HUP0200438A3 (en) 2002-02-06 2003-10-28 Egis Gyogyszergyar Nyilvanosan Novel clopidogrel hydrochloride polymorphs, process for the preparation thereof, their use and pharmaceutical compositions containing them
WO2003074072A1 (en) * 2002-03-01 2003-09-12 Chiron Corporation Methods and compositions for the treatment of ischemia
ITMI20020933A1 (it) * 2002-05-03 2003-11-03 Danimite Dipharma S P A Procedimento per la sintesi di clopidogrel
ES2369640T3 (es) * 2002-05-24 2011-12-02 Angiotech International Ag Composiciones y métodos para revestir implantes médicos.
IL166593A0 (en) 2002-08-02 2006-01-15 Racemization and enantiomer separation of clopidogrel
US6800759B2 (en) * 2002-08-02 2004-10-05 Teva Pharmaceutical Industries Ltd. Racemization and enantiomer separation of clopidogrel
CZ297472B6 (cs) * 2002-08-27 2006-12-13 Zentiva, A.S. Zpusob výroby clopidogrelu hydrogensulfátu krystalické formy I
MXPA05002728A (es) 2002-09-13 2005-07-25 Cydex Inc Capsulas que contienen composiciones de relleno acuoso estabilizadas con ciclodextrina derivada.
AU2003270861A1 (en) 2002-10-02 2004-04-23 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
JP4602085B2 (ja) * 2002-10-09 2010-12-22 セルリアン・ファーマ・インコーポレイテッド シクロデキストリンを基材とした物質、組成物及びこれらと関連する用途
US20040115287A1 (en) 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
DE10305984A1 (de) 2003-02-13 2004-09-02 Helm Ag Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
AU2003216707A1 (en) * 2003-03-10 2004-09-30 Hetero Drugs Limited Amorphous clopidogrel hydrogen sulfate
AU2003238664A1 (en) * 2003-03-12 2004-09-30 Cadila Healthcare Limited Polymorphs and amorphous form of (s) - (+) -clopidogrel bisulfate
US6858734B2 (en) * 2003-04-23 2005-02-22 Rhodia Pharma Solutions Inc. Preparation of (S)-Clopidogrel and related compounds
JP2006525328A (ja) 2003-05-05 2006-11-09 イーライ リリー アンド カンパニー 心疾患の治療方法
EP1558220B1 (en) * 2003-07-24 2010-02-10 Wockhardt Limited Oral compositions for treatment of diabetes
US20050096365A1 (en) 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
EP1729724A4 (en) 2003-12-31 2008-07-23 Cydex Inc INHALATION FORMULATION WITH SULFOALKYL ETHER GAMMA CYCLODEXTRIN AND CORTICOSTEROID
SI21748A (sl) 2004-03-26 2005-10-31 Diagen D.O.O. Inkluzijski kompleksi klopidogrela in njegovih kislinskih adicijskih soli, postopek za njihovo pripravo, farmacevtski pripravki, ki vsebujejo te komplekse in njihova uporaba za zdravljenje tromboze
JP4550884B2 (ja) * 2004-04-09 2010-09-22 ハンミ ファーム． シーオー．， エルティーディー． 結晶性クロピドグレルナフタレンスルホン酸塩又はその水和物、その製造方法及びそれを含む医薬組成物
US20050250738A1 (en) * 2004-05-06 2005-11-10 Mosher Gerold L Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
EP1761283A2 (en) 2004-06-07 2007-03-14 California Institute Of Technology Biodegradable drug-polymer delivery system
US20060047121A1 (en) 2004-09-01 2006-03-02 Sawant Kamlesh D Novel process for preparation of clopidogrel bisulfate polymorph - Form I
KR20070052780A (ko) 2004-09-21 2007-05-22 테바 파마슈티컬 인더스트리즈 리미티드 결정질 클로피도그렐 브롬산염 및 이의 제조 방법
US7446200B2 (en) * 2004-10-04 2008-11-04 Usv, Ltd. Rapid resolution process of clopidogrel base and a process for preparation of clopidogrel bisulfate polymorph-form I
JP2008526896A (ja) 2005-02-24 2008-07-24 テバ ファーマシューティカル インダストリーズ リミティド 医薬製剤に適したグロピドグレル塩基及びその調製
TWI318571B (en) 2005-06-10 2009-12-21 Lilly Co Eli Formulation of a thienopyridine platelet aggregation inhibitor
US20070003615A1 (en) * 2005-06-13 2007-01-04 Elan Pharma International Limited Nanoparticulate clopidogrel and aspirin combination formulations
EP1893205A4 (en) 2005-06-17 2010-06-30 Lilly Co Eli DOSAGE FOR PRASUGREL
EP1898922A4 (en) * 2005-07-04 2012-03-14 Ramu Krishnan MEDICINE OR IMPROVED PHARMACEUTICAL COMPOUNDS AND PREPARATION THEREOF
JP2009504737A (ja) 2005-08-19 2009-02-05 イーライ リリー アンド カンパニー 脈管疾患の治療又は予防のためのｐａｒ−１／ｐａｒ−４阻害剤の使用
KR100783286B1 (ko) * 2005-09-26 2007-12-06 주식회사종근당 클로피도그렐 우선성 광학이성체의 유리염기를 함유하는고형의 약제학적 조성물
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
CN100503647C (zh) 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
US7658913B2 (en) * 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
US20100062066A1 (en) 2006-11-14 2010-03-11 Acusphere, Inc Formulations of Tetrahydropyridine Antiplatelet Agents for Parenteral or Oral Administration
MX2009006037A (es) 2006-12-07 2009-06-16 Lilly Co Eli Un articulo de manufactura para prasugrel.
KR20080055355A (ko) 2006-12-15 2008-06-19 에스케이케미칼주식회사 보관안정성이 우수한 클로피도그렐 함유 포접 복합체
KR20080055356A (ko) 2006-12-15 2008-06-19 에스케이케미칼주식회사 보관안정성이 우수한 클로피도그렐 함유 포접 복합체
SI2123656T1 (sl) 2007-03-02 2014-09-30 Daiichi Sankyo Company, Limited Postopek izdelave hidroklorid prasugrela visoke ÄŤistosti
DK2152078T3 (da) * 2007-04-27 2021-02-08 Cydex Pharmaceuticals Inc Formuleringer indeholdende clopidogrel og sulfoalkylethercyclodextrin og anvendelsesfremgangsmåder
WO2009018069A2 (en) 2007-07-30 2009-02-05 Cydex Pharmaceuticals, Inc Mixtures of cyclodextrin derivatives
WO2009054095A1 (ja) 2007-10-22 2009-04-30 Advantest Corporation 周波数変換装置および直交変調器
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
CA2730995C (en) 2008-07-17 2016-11-22 Micell Technologies, Inc. Drug delivery medical device
EP2325187A4 (en) 2008-08-02 2011-09-28 Lunan Pharm Group Corp PRASUGREL HYDROGENOSULFATE, ITS MEDICINAL COMPOUND AND USE THEREOF
CN101390856B (zh) 2008-11-10 2011-04-20 重庆莱美药业股份有限公司 氯吡格雷的固体制剂及其制备方法
PT3100728T (pt) 2009-05-13 2020-02-21 Cydex Pharmaceuticals Inc Composições farmacêuticas que compreendem prasugrel e derivados da ciclodextrina e métodos de produção e utilização dos mesmos
CN102232949A (zh) 2010-04-27 2011-11-09 孙远 提高药物溶出度的组合物及其制备方法

Also Published As

Publication number Publication date
NZ581362A (en) 2011-07-29
SI2152078T1 (sl) 2021-08-31
CA2921601A1 (en) 2008-11-06
IL201776A0 (en) 2010-06-16
EP2152078B8 (en) 2021-03-17
US20100292268A1 (en) 2010-11-18
WO2008134601A1 (en) 2008-11-06
JP2018021071A (ja) 2018-02-08
IL201776A (en) 2016-05-31
US9623045B2 (en) 2017-04-18
CN101686681A (zh) 2010-03-31
RU2470636C2 (ru) 2012-12-27
CA2921601C (en) 2018-04-24
JP2010525083A (ja) 2010-07-22
JP2015091857A (ja) 2015-05-14
CN104800210A (zh) 2015-07-29
US10034947B2 (en) 2018-07-31
US20130129700A1 (en) 2013-05-23
CN104800210B (zh) 2019-08-06
EP3766493A1 (en) 2021-01-20
US10512697B2 (en) 2019-12-24
JP5681485B2 (ja) 2015-03-11
CN101686681B (zh) 2015-04-01
RU2009143991A (ru) 2011-06-10
MX2009011619A (es) 2010-01-18
US20150025243A1 (en) 2015-01-22
JP6076382B2 (ja) 2017-02-08
HK1212909A1 (zh) 2016-06-24
BRPI0809838B1 (pt) 2021-10-05
US8853236B2 (en) 2014-10-07
US8343995B2 (en) 2013-01-01
WO2008134600A1 (en) 2008-11-06
US20170173178A1 (en) 2017-06-22
EP2152078B1 (en) 2021-01-13
DK2152078T3 (da) 2021-02-08
KR101753131B1 (ko) 2017-07-04
EP3766493B1 (en) 2023-08-23
EP2152078A1 (en) 2010-02-17
JP2017061533A (ja) 2017-03-30
US20160058786A1 (en) 2016-03-03
KR20160033792A (ko) 2016-03-28
AU2008245550B2 (en) 2013-10-10
KR20100017366A (ko) 2010-02-16
ES2855700T3 (es) 2021-09-24
CA2685331A1 (en) 2008-11-06
AU2008245550A1 (en) 2008-11-06
BRPI0809838A2 (pt) 2019-01-15
US9125945B2 (en) 2015-09-08
EP2152078A4 (en) 2011-06-15
CA2685331C (en) 2016-07-05
KR20150041173A (ko) 2015-04-15
JP6496381B2 (ja) 2019-04-03
US20180326090A1 (en) 2018-11-15
JP6228286B2 (ja) 2017-11-08

Similar Documents

Publication Publication Date Title
HK1212909A1 (zh) 包含氯吡格雷和磺基烷基醚環糊精的製劑和其使用方法
HUS2000026I1 (hu) Anti-CD79b antitestek és immunkonjugátumok és alkalmazási eljárások
IL256924B (en) Prebiotic formulations and methods of using them
IL196185A0 (en) Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
HK1210420A1 (en) Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
IL215123A0 (en) Polymer-agent conjugates, particles, compositions, and related methods of use
EP2297268A4 (en) HIGH DENSITY COLUMN FLUIDS AND ITS USE
EP2268673A4 (en) POLYPEPTIDE-POLYMER CONJUGATES AND METHODS OF USE THEREOF
EP3269737C0 (en) ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
EP2364161A4 (en) COMPOSITIONS CONTAINING SATIOGENES AND METHODS OF USE
HRP20160902T1 (hr) Pripravci i postupci uporabe forbolskih estera
EP2173822A4 (en) INK FORMULATIONS AND METHOD FOR PRODUCING INK FORMS
EP2139909A4 (en) PREQ1-RIBOSWITCHES AND METHOD AND COMPOSITIONS FOR USE BY AND WITH PREQ1-RIBOSWITCHES
ZA200907727B (en) Cinnamaldehyde formulations and methods of use
EP2262488A4 (en) SOLID COMPLEX OF COLCHICINE; THEIR METHODS OF MANUFACTURE; AND THEIR METHODS OF USE
HK1166610A1 (en) Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof